ACTRN12616000922471已完成2 期
A Phase I, Randomized, Placebo-Controlled, Double Blind, Trial of Safety, Tolerabilityand Efficacy Study of Topical AKP-11 Administration to Participants with Arthritis.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Males or females aged 18-65 years (inclusive) at the time of screening.
- •Primary complaint or clinical findings of inflammatory arthritis, specifically rheumatoid arthritis or gout.
- •Stable disease in both extent and severity for at least two weeks prior to the commencement of study treatment.
- •An average baseline pain score of greater than 4 on a 11-point NRS (0 to 10) Scale over 3 days prior to randomization.
- •Baseline Swelling or Tenderness score 1 prior to randomization.
- •Able to provide written informed consent prior to the performance of any study specific procedures.
- •BMI between 18.0 and 40.0 kg/m2, inclusive.
- •Female subjects of non-childbearing potential, defined as (1) having a documented tubal ligation at least 6 weeks prior to dosing; (2) having had a surgical bilateral oophorectomy (with or without hysterectomy); (3) at least 12 months of spontaneous amenorrhoea with follicle stimulating hormone (FSH) greater than 40 MIU/ml.
- •Female participants of child-bearing potential with negative urine pregnancy test at screening and negative urine pregnancy test at check-in (Day 1), AND; a. Agree to abstinence for the duration of the study and until 4 weeks after dosing with study drug, if this is in line with the usual and preferred lifestyle; b. OR agree to use condoms plus one other acceptable form of contraception; i.e. intrauterine device, hormonal contraception (oral,injected or implanted) or a female diaphragm,from screening until 4 weeks after dosing with study drug;
- •c. OR has only same-sex partners; d. OR has a vasectomized partner, which should
- •be the sole partner for that participant.
- •Male participants with female partners of childbearing potential must agree to abstinence if this is in line with the usual lifestyle, or to use condoms plus partner use of an acceptable contraceptive (intrauterine device, hormonal contraception such as oral, injected or implanted; or male condom plus female diaphragm or cervical cap) for the duration of the study and until 4 weeks after dosing with study drug.
- •Negative test results for Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C at the time of screening.
- •Negative drug screening test (drugs of abuse; Creatinine control, testing for amphetamines,
- •barbiturates, cocaine, cannabinoids and benzodiazepines) result (urine test) at the time of
- •A 12-lead ECG at screening that in the opinion of the investigator, has no abnormalities that compromise subject’s safety in this study.
- •Participants who are willing and able to comply with all study assessments and adhere to the protocol schedule.
排除标准
- •History of allergy and/or hypersensitivity to any of the stated ingredients of the formulations.
- •Current treatment with immunosuppressant agents or systemic corticosteroids.
- •Expected change in existing analgesia, and antiinflammatory therapy.
- •Recent history of major joint injury or surgery.
- •Major chronic inflammatory disease (e.g Crohn’s disease, SLE) excluding rheumatoid arthritis,
- •Congenital or acquired immunodeficiency or cancer prone syndrome.
- •History of malignancy (other than adequately treated skin carcinoma or carcinoma-in-situ of the cervix).
- •Treatment with any of the following within 4 weeks prior to the commencement of study treatment and for the duration of the study: systemic retinoids; immunosuppressant agents (e.g. methotrexate, cyclosporine, azathioprine, thioguanine prednisone, prednisolone, hydroxyurea or mycophenolate mofetil);
- •Have received any investigational research agent or therapeutic biologic within 30 days or 5 half-lives (whichever is longer) prior to the first dose of Investigational Product.
- •Have received an investigational vaccine within 6 months, a live attenuated vaccine within 60 days or a registered vaccine within 30 days prior to the first dose of the Investigational Product.
- •Have evidence of drug or alcohol abuse within 6 months prior to screening visit.
- •Have clinical signs of active infection and/or a temperature of greater than 38.0 degrees C at the time of screening. Study entry may be deferred at the discretion of the Principal Investigator.
- •Anticipate surgery within the trial period or history of major surgery within 3 months of screening.
- •History of hypersensitivity to any other S1P1 receptor modulator.
- •A depot injection or an implant of any drug within 3 months prior to administration of study treatment, with the exception of a contraceptive implant.
- •Participants who are unable to return for all scheduled study visits.
- •Any clinically significant history or presence of neurological, endocrinal, cardiovascular, pulmonary, haematological, malignant, immunologic, psychiatric, metabolic or other uncontrolled systemic disease, with the exclusion of arthritis.
- •Any clinically significant abnormality at screening determined by medical history, physical examination, blood chemistry, haematology, urinalysis and an 12-lead- ECG.
研究者
相似试验
已完成
不适用
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy ParticipantsAlzheimers10012303Alzheimer's DiseaseNL-OMON51440Denali Therapeutics Inc.80
已完成
1 期
Study of ZYN002 (cannabidiol gel) in 40 Healthy VolunteersMental Health - Other mental health disordersNeurological - EpilepsyMusculoskeletal - OsteoarthritisHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersEpilepsyFragile X SyndromeOsteoarthritisACTRN12618000183280Zynerba Pharmaceuticals Pty. Ltd.40
已完成
不适用
A Phase I, Randomized, Placebo-controlled, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen® (Poly I:Poly C12U) in Healthy SubjectsCoronaCOVID-19SARS-CoV-210047438NL-OMON50834AIM ImmunoTech Inc.40
已完成
1 期
A first in human study assessing the safety and pharmacokinetics (blood levels) of RA101495.ACTRN12615001143516Clinical Network Services Pty Ltd40
已完成
1 期
A first in Human single-Center Study To Evaluate the effectiveness and Safety Of A Live Attenuated Dengue Vaccine (KD-382) In Healthy AdultsInfection - Other infectious diseasesInflammatory and Immune System - Normal development and function of the immune systemDengue FeverACTRN12618001027202KM Biologics Co., Ltd.60